Shares of Poniard Pharmaceuticals Inc. tumbled 76 percent on disappointing data from its Phase III trial of picoplatin in small-cell lung cancer, news that's certain to hamper ongoing discussions for a much-needed partnership. (BioWorld Today)
Last year's crumbling markets might have forced Astex Therapeutics Ltd. to delay plans for an initial public offering, but the Cambridge, UK-based firm is hardly hurting for cash, thanks to fragment chemistry-based discovery deal with GlaxoSmithKline plc. (BioWorld Today)
As Shire plc gears up for an early 2010 PDUFA date for its enzyme replacement therapy velaglucerase alfa in Gaucher's disease, potential competitor Protalix BioTherapeutics Inc. reportedly is being eyed by pharma giant Pfizer Inc. for a possible collaboration or even outright acquisition. (BioWorld Today)
